Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
AIMS: Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19.
METHODS: CORONADO is a nationwide observational study that included patients with diabetes hospitalised for COVID-19 between March 10 and April 10, 2020 in 68 French centres. The primary outcome combined tracheal intubation and/or death within 7 days of admission. A Kaplan-Meier survival curve was reported for death up to day 28. The association between metformin use and outcomes was then estimated in a logistic regression analysis after applying a propensity score inverse probability of treatment weighting approach.
RESULTS: Among the 2449 patients included, 1496 were metformin users and 953 were not. Compared with non-users, metformin users were younger with a lower prevalence of diabetic complications, but had more severe features of COVID-19 on admission. The primary endpoint occurred in 28.0% of metformin users (vs 29.0% in non-users, P = 0.6134) on day 7 and in 32.6% (vs 38.7%, P = 0.0023) on day 28. The mortality rate was lower in metformin users on day 7 (8.2 vs 16.1%, P < 0.0001) and on day 28 (16.0 vs 28.6%, P < 0.0001). After propensity score weighting was applied, the odds ratios for primary outcome and death (OR [95%CI], metformin users vs non-users) were 0.838 [0.649-1.082] and 0.688 [0.470-1.007] on day 7, then 0.783 [0.615-0.996] and 0.710 [0.537-0.938] on day 28, respectively.
CONCLUSION: Metformin use appeared to be associated with a lower risk of death in patients with diabetes hospitalised for COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Diabetes & metabolism - 47(2021), 5 vom: 10. Sept., Seite 101216 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 10.11.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diabet.2020.101216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318752336 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318752336 | ||
| 003 | DE-627 | ||
| 005 | 20231225170017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabet.2020.101216 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318752336 | ||
| 035 | |a (NLM)33309936 | ||
| 035 | |a (PII)S1262-3636(20)30273-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lalau, Jean-Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.11.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a AIMS: Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for COVID-19 | ||
| 520 | |a METHODS: CORONADO is a nationwide observational study that included patients with diabetes hospitalised for COVID-19 between March 10 and April 10, 2020 in 68 French centres. The primary outcome combined tracheal intubation and/or death within 7 days of admission. A Kaplan-Meier survival curve was reported for death up to day 28. The association between metformin use and outcomes was then estimated in a logistic regression analysis after applying a propensity score inverse probability of treatment weighting approach | ||
| 520 | |a RESULTS: Among the 2449 patients included, 1496 were metformin users and 953 were not. Compared with non-users, metformin users were younger with a lower prevalence of diabetic complications, but had more severe features of COVID-19 on admission. The primary endpoint occurred in 28.0% of metformin users (vs 29.0% in non-users, P = 0.6134) on day 7 and in 32.6% (vs 38.7%, P = 0.0023) on day 28. The mortality rate was lower in metformin users on day 7 (8.2 vs 16.1%, P < 0.0001) and on day 28 (16.0 vs 28.6%, P < 0.0001). After propensity score weighting was applied, the odds ratios for primary outcome and death (OR [95%CI], metformin users vs non-users) were 0.838 [0.649-1.082] and 0.688 [0.470-1.007] on day 7, then 0.783 [0.615-0.996] and 0.710 [0.537-0.938] on day 28, respectively | ||
| 520 | |a CONCLUSION: Metformin use appeared to be associated with a lower risk of death in patients with diabetes hospitalised for COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Death | |
| 650 | 4 | |a Mechanical ventilation | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a Propensity score | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 700 | 1 | |a Al-Salameh, Abdallah |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjadj, Samy |e verfasserin |4 aut | |
| 700 | 1 | |a Goronflot, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Wiernsperger, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Pichelin, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Allix, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Amadou, Coralie |e verfasserin |4 aut | |
| 700 | 1 | |a Bourron, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Duriez, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Gautier, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Dutour, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Gonfroy, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Gouet, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Joubert, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Julier, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Larger, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Marchand, Lucien |e verfasserin |4 aut | |
| 700 | 1 | |a Marre, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Olivier, Frédérique |e verfasserin |4 aut | |
| 700 | 1 | |a Prevost, Gaëtan |e verfasserin |4 aut | |
| 700 | 1 | |a Quiniou, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Raffaitin-Cardin, Christelle |e verfasserin |4 aut | |
| 700 | 1 | |a Roussel, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Saulnier, Pierre-Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Seret-Begue, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Thivolet, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Vatier, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Desailloud, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Wargny, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Gourdy, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Cariou, Bertrand |e verfasserin |4 aut | |
| 700 | 0 | |a CORONADO investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolism |d 1998 |g 47(2021), 5 vom: 10. Sept., Seite 101216 |w (DE-627)NLM086696130 |x 1878-1780 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:5 |g day:10 |g month:09 |g pages:101216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabet.2020.101216 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 5 |b 10 |c 09 |h 101216 | ||